MD430C2 - Method for human leucocytar interferone preparation - Google Patents

Method for human leucocytar interferone preparation

Info

Publication number
MD430C2
MD430C2 MD95-0076A MD950076A MD430C2 MD 430 C2 MD430 C2 MD 430C2 MD 950076 A MD950076 A MD 950076A MD 430 C2 MD430 C2 MD 430C2
Authority
MD
Moldova
Prior art keywords
pst
pbr
leucocytar
interferone
preparation
Prior art date
Application number
MD95-0076A
Other languages
Romanian (ro)
Russian (ru)
Inventor
Van Norman Goeddel David
Pestka Sidney
Original Assignee
F.Hoffmann-La Roche Ag
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag, Genentech, Inc. filed Critical F.Hoffmann-La Roche Ag
Publication of MD430C2 publication Critical patent/MD430C2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C12N15/71—Expression systems using regulatory sequences derived from the trp-operon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Application field: genetic engineering, leucocytar interferone preparation. The summary of the invention: the method comprises the DNA sequence detection and isolation and recombinant molecules construction, coding the polypeptide which possesses the immunologic and biologic activity of HIFN-α. there are obtained recombinant plasmide DNA, containing the Z-pBR 322 (Pst)HCIF-4c, Z-pBR 322 (Pst), HIF-2h, Z-pBR 322 (Pst) HcIF-SN-35, Z-pBR 322 (Pst) Hc1F-SN-42, Z-pKT287 (Pst) Hc1F-2h-AH6 DNA sequence as well as the sequences which are hybridizated with the mentioned insertions.
MD95-0076A 1980-07-01 1994-12-30 Method for human leucocytar interferone preparation MD430C2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16498680A 1980-07-01 1980-07-01
US18490980A 1980-09-08 1980-09-08
US20557880A 1980-11-10 1980-11-10
US06/256,204 US6610830B1 (en) 1980-07-01 1981-04-21 Microbial production of mature human leukocyte interferons

Publications (1)

Publication Number Publication Date
MD430C2 true MD430C2 (en) 1996-06-30

Family

ID=27389083

Family Applications (1)

Application Number Title Priority Date Filing Date
MD95-0076A MD430C2 (en) 1980-07-01 1994-12-30 Method for human leucocytar interferone preparation

Country Status (6)

Country Link
US (2) US6610830B1 (en)
KR (1) KR860001558B1 (en)
CA (1) CA1341583C (en)
GE (1) GEP20074163B (en)
MD (1) MD430C2 (en)
ZW (1) ZW14781A1 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835557B1 (en) * 1980-01-08 2004-12-28 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing human interferon-like polypeptides
FR2686899B1 (en) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
EP1274720A4 (en) 2000-04-12 2004-08-18 Human Genome Sciences Inc ALBUMIN FUSED PROTEINS
US7959910B2 (en) * 2000-07-31 2011-06-14 Biolex Therapeutics, Inc. C-terminally truncated interferon alpha variants
WO2002036627A2 (en) * 2000-11-03 2002-05-10 Pbl Biomedical Laboratories Interferons, uses and compositions related thereto
FR2822845B1 (en) * 2001-03-30 2003-12-12 Genodyssee NOVEL POLYNUCLEOTIDES COMPRISING FUNCTIONAL SNP-LIKE POLYMORPHISMS IN THE NUCLEOTIDE SEQUENCE OF THE IFN-ALPHA-21 GENE AS WELL AS NEW POLYPEPTIDES ENCODED BY THESE POLYNUCLEOTIDES AND THEIR THERAPEUTIC USES
AU2002346686A1 (en) * 2001-12-07 2003-06-23 Intermune, Inc. Compositions and method for treating hepatitis virus infection
PT1463751E (en) 2001-12-21 2013-08-26 Human Genome Sciences Inc ALBUMINE FUSION PROTEINS
KR101271635B1 (en) * 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 Albumin fusion proteins
DE60319114T2 (en) * 2002-08-31 2008-12-04 Cj Cheiljedang Corp. GLYCOSYLATED HUMAN INTERFERON ALPHA ISOFORM
CA2498319A1 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
US20040219131A1 (en) * 2002-11-18 2004-11-04 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
US7314613B2 (en) * 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
AU2003303636B2 (en) * 2002-12-26 2010-08-05 Mountain View Pharmaceuticals, Inc. Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
CN102319437B (en) 2002-12-26 2017-10-13 山景医药公司 Polymer conjugates of interferon-beta with enhanced biological utility
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
CN103755800B (en) 2004-02-02 2016-02-24 Ambrx公司 Modified human interferon polypeptides and its purposes
CA2566247A1 (en) * 2004-05-19 2005-12-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
US20060024272A1 (en) * 2004-07-29 2006-02-02 Large Scale Biology Corporation C-terminally truncated interferon
WO2006111745A2 (en) * 2005-04-20 2006-10-26 Viragen Incorporated Composition and method for treating viral infection
MX2007014524A (en) * 2005-05-18 2008-02-07 Maxygen Inc Evolved interferon-alpha polypeptides.
MX2007014889A (en) * 2005-05-26 2008-02-19 Schering Corp Interferon-igg fusion.
WO2006133088A2 (en) * 2005-06-03 2006-12-14 Ambrx, Inc. Improved human interferon molecules and their uses
US7770595B2 (en) * 2006-04-27 2010-08-10 Sko Flo Industries, Inc. Flow control valve
US8679472B1 (en) 2006-10-05 2014-03-25 Merck, Sharp & Dohme Corp. Crystal of human interferon alpha 2B in complex with zinc
WO2008127711A2 (en) * 2007-04-11 2008-10-23 Pestka Biomedical Laboratories, Inc. Interferons of rhesus and cynomolgus origin and uses thereof
KR20100019467A (en) 2007-05-02 2010-02-18 암브룩스, 인코포레이티드 Modified interferon beta polypeptides and their uses
AU2008279087A1 (en) * 2007-07-25 2009-01-29 Biolex Therapeutics, Inc. Controlled release interferon drug products and treatment of HCV infection using same
CN101636411B (en) * 2007-09-04 2013-01-09 厦门伯赛基因转录技术有限公司 Interferon alpha 2a modified by polyethylene glycol, synthesis process and application thereof
NZ602170A (en) 2008-02-08 2014-03-28 Ambrx Inc Modified leptin polypeptides and their uses
JP5675606B2 (en) 2008-07-08 2015-02-25 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム Novel inhibitor of signal transduction transcription factor (STAT) proliferation and activation
WO2012175700A1 (en) 2011-06-23 2012-12-27 Digna Biotech, S. L. Treatment of chronic hepatitis c with ifn-a5 combined with ifn-a2b in a cohort of patients
CA2866126A1 (en) 2012-03-03 2013-09-12 Immungene, Inc. Engineered antibody-interferon mutant fusion molecules
WO2013175487A2 (en) * 2012-03-30 2013-11-28 Krishnan Archana Rajesh Codon optimized sequence for an antiviral protein
CU24554B1 (en) * 2018-05-07 2021-11-04 Ct Inmunologia Molecular FUSION PROTEINS COMPOSED OF INTERLEUKIN 2 MUTEIN AND TYPE 1 INTERFERON

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MW3378A1 (en) 1977-11-08 1980-03-12 Genentech Inc Method and means for microbial polypeptide expression;synthetic dna and process therefor
US4411994A (en) 1978-06-08 1983-10-25 The President And Fellows Of Harvard College Protein synthesis
US4503035B1 (en) 1978-11-24 1996-03-19 Hoffmann La Roche Protein purification process and product
IN150740B (en) * 1978-11-24 1982-12-04 Hoffmann La Roche
US4332892A (en) 1979-01-15 1982-06-01 President And Fellows Of Harvard College Protein synthesis
ES479300A1 (en) 1979-04-04 1979-07-01 Cusi Lab An alpha-methyl-4(2'-thienyl-carbonyl)phenyl acetic acid derivative, process for its preparation and its pharmaceutical use.
US4342832A (en) 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4418149A (en) 1980-01-10 1983-11-29 President And Fellows Of Harvard College Fused hybrid gene
US4801685A (en) 1981-08-14 1989-01-31 Hoffmann-La Roche Inc. Microbial production of mature human leukocyte interferon K and L
US4810645A (en) 1981-08-14 1989-03-07 Hoffmann-La Roche Inc. Microbial production of mature human leukocyte interferon K and L

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Shigekazu N. et al. Synthensin E. coli of a polypeptide with human leukocyte interferon activity. Nature, v. 284, March, 1980, p. 316-320. *

Also Published As

Publication number Publication date
ZW14781A1 (en) 1982-04-21
GEP20074163B (en) 2007-07-10
US6482613B1 (en) 2002-11-19
CA1341583C (en) 2008-11-18
KR860001558B1 (en) 1986-10-04
KR830006422A (en) 1983-09-24
US6610830B1 (en) 2003-08-26

Similar Documents

Publication Publication Date Title
EP0653940A4 (en) GLOBAL MITOGENIC FACTORS, THEIR PREPARATION AND USE.
MD431C2 (en) Method for leukocytar interferone preparation
DK288183D0 (en) PROCEDURE FOR THE PREPARATION OF AN OLIGONUCLEOTIDE THERAPEUTIC AGENT
KR970000808B1 (en) Human proapolipoprotein a-1 expression
MY101972A (en) Primate interleukin - 4
AU1348083A (en) Dna sequences, recombinant dna molecules and preparations of cholera toxin
ZA859437B (en) Dna sequence encoding a hirudin-like protein and process for preparing such protein
DK188582A (en) BACILLUS CLONING VECTORS RECOMBINATION DNA MOLECULES BACILLUS VALUES TRANSFORMED THEREOF, AND PROCEDURES FOR EXPRESSION OF PROCESSED DNA SEQUENCES AND PREPARATION OF POLYPEPTIDES CODED THEREOF
ES8703490A1 (en) DNA encoding human tumor necrosis factor and human tumor necrosis factor polypeptide.
DE3586697D1 (en) Aktive thymopentin-analoga.
PT84089A (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
FI861653A7 (en) Isolated DNA compound encoding recombinant DNA isopenicillin N synthetase, vectors containing the same and method for producing isopenicillin N synthetase activity therewith
JPS615392B2 (en)
ZA947059B (en) Grb3-3 gene its variants and their uses
GB9215232D0 (en) Vaccines
GB2171703B (en) Expression-secretion vector for gene expression and protein secretion, recombinant dna including the vector, and method of producing proteins by use of the re
DK0643719T3 (en) Nucleic acid sequences encoding or complementary to nucleic acid sequences encoding interleukin 9 receptor
EP0770137A4 (en) Improvements in production of proteins in host cells
ATE215123T1 (en) OR-1, A WAIS RECEPTOR OF THE NUCLEAR RECEPTOR FAMILY
ES8800353A1 (en) MOLECULAR CLONING OF cDNA FOR HUMAN FACTOR VIIIR (VON WILLEBRAND FACTOR).
WO1990003394A3 (en) New limphokines, dna sequences coding for said limphokines and pharmaceutical compositions containing said limphokines
IT8521507A0 (en) CLONING VECTOR, RECOMBINANT DNA MOLECULES, STRAINS OF BACILLUS SUBTILIS TRANSFORMED WITH THE SAID MOLECULES AND METHODS FOR THE EXPRESSION OF HETEROLOGOUS GENES AND PRODUCTION AND SECRETION OF PROTEINS CODED BY THE SAID GENES.
MY134493A (en) Thrombopoietin peptides, fragments, nucleic acids encoding the same, and method
Hitchcock Commercial prospects for genetic engineering not so dismal